Literature DB >> 12765299

Anti-prothrombin antibodies cause thrombosis in a novel qualitative ex-vivo animal model.

S Haj-Yahia1, S Haj-Yahja, Y Sherer, M Blank, H Kaetsu, A Smolinsky, Y Shoenfeld.   

Abstract

Anti-prothrombin antibodies (aPT) are associated with thrombotic manifestations, and their association with reproductive failure is debatable. The aim of this study was to examine whether aPT could induce thrombosis and other clinical manifestations of the anti-phospholipid syndrome (APS). Mice were immunized with either prothrombin, beta2-glycoprotein-I (beta2GPI), or beta2GPI followed by prothrombin. The presence of clinical manifestation of APS, including thrombocytopenia, lupus anticoagulant and fetal resorption rates, was evaluated in all mice groups compared with nonimmunized mice. Thrombosis was studied in a novel ex-vivo model in which the aorta was sutured for 1 min and the presence or absence of visible thrombus was qualitatively evaluated. Immunized mice developed high autoantibody levels directed towards their immunizing autoantigens. The groups immunized with beta2GPI or beta2GPI/prothrombin, but not with prothrombin alone, developed prolonged aPTT, thrombocytopenia and increased fetal resorption rate. All prothrombin-immunized mice as well as most beta2GPI/prothrombin-immunized mice developed visible thrombus within the aorta. Some beta2GPI immunized mice developed very mild thrombus. None of the CFA/PBS-injected or the nonimmunized mice developed such thrombus. Active immunization with prothrombin or beta2GPI/prothrombin is associated with prothrombotic activity of blood in an ex-vivo model. This is the first direct evidence for thrombus induction by aPT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12765299     DOI: 10.1191/0961203303lu370oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  5 in total

1.  Clinical performance of antibodies to prothrombin and thrombin in Chinese patients with antiphospholipid syndrome: potential interest in discriminating patients with thrombotic events and non-thrombotic events.

Authors:  Shulan Zhang; Ziyan Wu; Jing Li; Ping Li; Si Chen; Xiaoting Wen; Liubing Li; Wen Zhang; Jiuliang Zhao; Fengchun Zhang; Yongzhe Li
Journal:  Rheumatol Int       Date:  2016-11-02       Impact factor: 2.631

Review 2.  Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.

Authors:  Savino Sciascia; Mary-Carmen Amigo; Dario Roccatello; Munther Khamashta
Journal:  Nat Rev Rheumatol       Date:  2017-08-03       Impact factor: 20.543

3.  Prevalence and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with venous and arterial thrombosis.

Authors:  Iván Palomo; Jaime Pereira; Marcelo Alarcón; Marcela Vásquez; Carmen Pinochet; María T Vélez; Jorge Sandoval; Gloria Icaza; Silvia Pierangeli
Journal:  Clin Rheumatol       Date:  2004-01-31       Impact factor: 2.980

4.  Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis.

Authors:  Mathivanan Chinnaraj; William Planer; Vittorio Pengo; Nicola Pozzi
Journal:  Blood Adv       Date:  2019-06-11

Review 5.  Recent advances in understanding antiphospholipid syndrome.

Authors:  Maria Laura Bertolaccini; Giovanni Sanna
Journal:  F1000Res       Date:  2016-12-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.